Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response after COVID-19 mRNA vaccination in children with cancer
2021-003388-90Phase 4Completed
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Antibody-based immune response at 28 days after second vaccination. Started Jun 2021; status: completed.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-003388-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003388-90.